Willow Tirzepatide Review: Cost, a Thin Public Record & Honest Verdict (2026)

Willow is a telehealth provider offering compounded GLP-1 medications in both tablet and injectable formats, at $399/month for tirzepatide at the starting dose. Every fact here comes from the company's own published program.

What Willow is

Willow (startwillow.com) is a telehealth provider, offering both compounded semaglutide and tirzepatide, with an unusual dual tablet-and-injectable format option. An online intake is reviewed by a licensed clinician, and pricing is published before you start the intake.

What Willow costs

Tirzepatide starts at $399/month at the starting dose — above the median for compounded tirzepatide.

The brand-vs-compounded question

Willow dispenses compounded semaglutide and tirzepatide. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Willow's real strength is the tablet-and-injectable format choice is a genuine convenience for needle-averse patients. But the trade-off is significant: this review found very limited public information about the program beyond format and starting price — no named pharmacy, no LegitScript badge, no disclosed state coverage, and no named medical staff. As with any GLP-1 program, and especially one with this little public detail, ask directly about pharmacy sourcing, state licensing, and clinical staff before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Willow's tablet-and-injectable choice is a real convenience, but the thin public record around pharmacy sourcing and clinical staff is worth asking about directly before committing. For a provider with fuller public disclosure, compare it against Vitara RX or Vytora Health. See our best tirzepatide providers ranking for the full field.